| Name | Title | Contact Details |
|---|
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and a robust gene therapy pipeline and growth platform for lysosomal storage disorders, we are committed to changing the lives of people with these life-threatening conditions. Across the organization, our team is united by our passion for making a difference, and committed to pushing ideas as far and as fast as possible. The needs of people living with rare diseases are at the center of our inventive science, our commercial organization, and our clinical programs. Every member of the Amicus Therapeutics team works to make a meaningful difference for the communities that we serve. Several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. Our global footprint spans 27 countries, including our global headquarters in Cranbury, NJ and international headquarters in Gerrards Cross UK. Additional international office locations include Australia, Canada, France, Japan, Germany, Italy, The Netherlands, and Spain.
Our mission at Kelyniam is to apply 3D printing and rapid prototyping technology to create innovative medical products that improve the lives of physicians and their patients.
Armada Health Care is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase`s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol `TTPH.` Tetraphase is well positioned to be a major player in the multidrug-resistant arena.
Concept Life Sciences provides integrated, high quality drug discovery, development and analytical services to the life science sector. Formed as a result of targeted acquisition and organic growth, the Company has the in-house expertise and resource to support customers with projects spanning from target discovery to the clinic, adding value and IP throughout the discovery pathway. With a track record of delivering knowledge-based, science-led solutions, the Company employs over 700 FTEs, including more than 500 highly skilled, experienced scientists, supporting its global client base from 11 state of the art laboratory facilities.